Innate Pharma Files 6-K, Announces Press Release
Ticker: IPHYF · Form: 6-K · Filed: May 27, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | May 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K on 5/27, likely with news from their press release.
AI Summary
Innate Pharma SA filed a Form 6-K on May 27, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational details beyond the announcement of the press release.
Why It Matters
This filing indicates Innate Pharma is making a public announcement, which could contain material information for investors regarding its business or financial status.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily announces the issuance of a press release, without providing new financial data or significant operational updates within the filing itself.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- May 27, 2025 (date) — Filing date and press release date
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release issued by Innate Pharma SA on May 27, 2025.
What is the filing date of this Form 6-K?
The Form 6-K was filed on May 27, 2025.
Does this filing include a Form 20-F or Form 40-F?
The filing indicates that Innate Pharma SA files annual reports under cover of Form 20-F.
What is the principal executive office address of Innate Pharma SA?
The principal executive office address is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated May 27, 2025, is included with this 6-K filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 27, 2025 regarding Innate Pharma SA (IPHYF).